Trial | NCT00981318  Report issue

Title

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc in Experienced Patients

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Terminated

  • Study Participants

    3
This is a study to assess the response of lopinavir/ritonavir plus maraviroc (with no nucleoside medications) in HIV patients failing their initial antiviral therapy.
As long-term toxicity to many of the nucleoside medications have become known, interest has increased in treatment regimens that do not use these medications. This study is to assess the response of one such "nucleoside-sparing" therapy in patients who are showing failure to their initial nucleoside-containing treatment regimen.
Study Started
Dec 31
2009
Primary Completion
May 31
2015
Study Completion
May 31
2015
Last Update
Jun 23
2015
Estimate

Drug lopinavir/ritonavir plus maraviroc

lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid

  • Other names: Kaletra, lopinavir, Selzentry

lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid Other

single arm

Criteria 

Inclusion Criteria:

HIV viral load > 1,000 on current antiviral medications
No resistance to study medications
Over 18 years of age

Exclusion Criteria:

Hepatitis B co-infection
Pregnancy
Previous therapy with either of the study medications
Ongoing substance abuse
Significant history of other physical disease
No Results Posted